Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients

International Journal of Cancer

Volumn 133, Issue 1, 2013, Pages 149-155

  Lilleby, Wolfgang ^a   Stensvold, Andreas ^a   Mills, Ian G ^b,c   Nesland, Jahn M ^b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

disseminated tumor cells; prostate cancer; survival

Indexed keywords

ANDROGEN RECEPTOR ANTAGONIST; CYTOKERATIN ANTIBODY;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE MARROW BIOPSY; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CELL HOMING; DISSEMINATED CANCER; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MONOTHERAPY; ONSET AGE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT DURATION;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BONE MARROW; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; TUMOR MARKERS, BIOLOGICAL;

EID: 84876678926     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28002     Document Type: Article

References (27)

1. Cheng L, Zincke H, Blute ML, et al. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001; 91: 66-73.
2. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80.
3. Kollermann J, Weikert S, Schostak M, et al. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol 2008; 26: 4928-33.
4. Weckermann D, Muller P, Wawroschek F, et al. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J Urol 2001; 166: 699-703.
5. Berg A, Berner A, Lilleby W, et al. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int J Cancer 2007; 120: 1603-9.
6. Danila DC, Fleisher M, Scher HI,. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011; 17: 3903-12.
7. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-9.
8. Berg A, Bruland OS, Fossa SD, et al. Disseminated tumor cells in bone marrow following definitive radiotherapy for intermediate or high-risk prostate cancer. Prostate 2008; 68: 1607-14.
9. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373: 301-8.
10. Borgen E, Naume B, Nesland JM, et al. Standardization of the immunocytochemical detection of cancer cells in BM and blood. I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999; 1: 377-88.
11. Borgen E, Pantel K, Schlimok G, et al. A European interlaboratory testing of three well-known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow. Cytometry B Clin Cytom 2006; 70: 400-9.
12. Bianco FJ, Jr, Wood DP, Jr, Gomes de OJ, et al. Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer. Prostate 2001; 49: 235-42.
13. Weckermann D, Polzer B, Ragg T, et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol 2009; 27: 1549-56.
14. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7.
15. Mathiesen RR, Borgen E, Renolen A, et al. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Res 2012; 14: R117.
16. Stott SL, Hsu CH, Tsukrov DI, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci USA 2010; 107: 18392-7.
17. Gradilone A, Naso G, Raimondi C, et al. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Ann Oncol 2011; 22: 86-92.
18. Solberg A, Haugen OA, Viset T, et al. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial. Int J Radiat Oncol Biol Phys 2011; 80: 55-61.
19. Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008; 71: 1028-33.
20. Coen JJ, Zietman AL, Thakral H, et al. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 2002; 20: 3199-205.
21. Klein CA,. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009; 9: 302-12.
22. Scher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: areanalysis of IMMC38 trial data. Lancet Oncol 2009; 10: 233-9.
23. Klarmann GJ, Hurt EM, Mathews LA, et al. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 2009; 26: 433-46.
24. Pantel K, Aignherr C, Kollermann J, et al. Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer. Eur J Cancer 1995; 31A: 1627-32.
25. Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-90.
26. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450: 1235-9.
27. Germann M, Wetterwald A, Guzman-Ramirez N, et al. Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells 2012; 30: 1076-86.